Here’s more evidence that hematopoietic stem cell transplant (HSCT) works better than some disease-modifying therapies (DMTs) at reducing multiple sclerosis (MS) progression. In this study, only three of 52 patients in the HSCT group had disease progression after a year compared to 34 of 51 in the DMT group. Progression increased over time, but significantly less in the HSCT group. Click on the headline to read the full story.
Autologous hematopoietic stem cell transplant is better than disease-modifying therapies (DMT) at reducing the risk of disease progression in patients with relapsing-remitting multiple sclerosis (RRMS), results from the MIST clinical trial show.
The study “Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis – A Randomized Clinical Trial” was published in the journal JAMA.
Mindfulness Protects Against Depression, Anxiety, Fatigue, and Sleep Issues in MS Patients, Study Finds
Treating MS symptoms can involve more than medications and physical therapy. This study reports that focusing your mind can help you to have a better quality of life. In addition to the news story above, one of my “MS Wire” columns last week focused on a program that uses mindfulness specifically for MS.
The disease-modifying therapy Ocrevus (ocrelizumab) was designed to attack B-cells, while the DMT Lemtrada (alemtuzumab) was designed to attack both B- and T-cells. The study reports that Ocrevus may also deplete some T-cells as it attempts to halt MS disease progression.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?